Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to asses...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Joao Manuel Santos, Riikka Havunen, Sadia Zafar, Otto Hemminki, Camilla Heiniö, Eleonora Munaro, Mikko Siurala, Suvi Sorsa, Tuomas Mirtti, Petrus Järvinen, Markus Mildh, Harry Nisen, Antti Rannikko, Marjukka Anttila, Anna Kanerva, Akseli Hemminki
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2020-01-01
coleção:	OncoImmunology
Assuntos:	oncolytic virus adenovirus checkpoint inhibitors immunotherapy tumor microenvironment
Acesso em linha:	http://dx.doi.org/10.1080/2162402X.2020.1761229
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!